Proteases in Patients With Prostate Cancer That Has Spread to the Bone
NCT ID: NCT00899665
Last Updated: 2014-02-11
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
31 participants
OBSERVATIONAL
2001-07-31
2008-01-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
PURPOSE: This laboratory study is comparing proteases (enzymes that break down protein) in patients with prostate cancer that has spread to the bone with patients who do not have cancer that has spread to the bone.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Study of a Polymorphism in Patients With Prostate Cancer
NCT00900185
Biomarkers of Bone Resorption in Metastatic Prostate Cancer
NCT01233557
PRostate Cancer Individual Signature Evaluation Trial in Patients Undergoing Scheduled Prostate Biopsy
NCT00966095
Evaluation of a Blood Biomarker to Try and Distinguish Between the Presence or Absence of Aggressive Prostate Cancer
NCT03256630
Efficacy and Safety of Organoid-Based Drug Sensitivity Screening to Guide the Treatment of mCRPC Patients Progressed After First-line Treatment
NCT06529549
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
* Examine the roles of proteases and protease-associated molecules in bone metastases in patients with metastatic prostate cancer.
OUTLINE: Patients undergo bone marrow aspiration and core bone biopsies. Tissues are analyzed by immunohistochemistry methods, in situ hybridization assays, gelatin zymography and/or Western blot analysis, and gene profiling analysis in order to visualize and quantitate protease or protease-related levels.
PROJECTED ACCRUAL: A total of 50 patients will be accrued for this study.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
fluorescence in situ hybridization
microarray analysis
molecular diagnostic method
immunohistochemistry staining method
laboratory biomarker analysis
biopsy
immunoscintigraphy
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Meets 1 of the following criteria:
* Diagnosis of metastatic prostate cancer
* Patients with documented bone metastases on radiologic imaging studies must undergo bone marrow biopsy
* Male patients ≥ 50 years of age without cancer who are scheduled to undergo bone biopsy for other clinically indicated reasons, including any of the following:
* Myelodysplasia
* Anemia
* Monoclonal gammopathy of undetermined significance
* Male or female patients ≥ 40 years of age without metastatic bone cancer who are scheduled to undergo an orthopedic procedure involving removal of bone specimen
PATIENT CHARACTERISTICS:
* See Disease Characteristics
PRIOR CONCURRENT THERAPY:
* Not specified
40 Years
MALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Cancer Institute (NCI)
NIH
Barbara Ann Karmanos Cancer Institute
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Michael L. Cher, MD
Role: STUDY_CHAIR
Barbara Ann Karmanos Cancer Institute
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Barbara Ann Karmanos Cancer Institute
Detroit, Michigan, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
WSU-D-2111
Identifier Type: -
Identifier Source: secondary_id
WSU-12-35-99(M02)
Identifier Type: -
Identifier Source: secondary_id
CDR0000483773
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.